Abstract | BACKGROUND: METHODS: RESULTS: Co-administration of YSL and high-dose doxorubicin (6 mg/kg every other day) prolonged the survival time of tumor-bearing mice as compared to high-dose doxorubicin alone. As well, the anti- tumor effects of mid- and low-dose doxorubicin (2 and 0.7 mg/kg every other day, respectively) were enhanced when supplemented with YSL; the tumor growth inhibition rates for YSL plus doxorubicin were greater than the inhibition rates for the same dosages of doxorubicin alone. The combination of YSL and doxorubicin decreased chemotherapy-associated weight loss, leukocyte depression, and heart, liver, and kidney damage as compared to doxorubicin alone. CONCLUSION:
|
Authors | Zhi-feng Zhu, Li-juan Chen, Rong Lu, Jing Jia, Yu Liang, Qiong Xu, Chun-lei Zhou, Li Wang, Song Wang, Zhi Yao |
Journal | BMC cancer
(BMC Cancer)
Vol. 8
Pg. 342
(Nov 25 2008)
ISSN: 1471-2407 [Electronic] England |
PMID | 19025669
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Oligopeptides
- Doxorubicin
- H-Tyr-Ser-Leu-OH
|
Topics |
- Animals
- Antineoplastic Combined Chemotherapy Protocols
(pharmacology)
- Cell Line, Tumor
- Doxorubicin
(administration & dosage)
- Drug Synergism
- Female
- Humans
- Liver Neoplasms, Experimental
(drug therapy)
- Mice
- Mice, Nude
- Oligopeptides
(administration & dosage)
- Xenograft Model Antitumor Assays
|